Menu

Dengue Fever

Our team at IBT Bioservices has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against arboviruses including Chikungunya, Dengue, and Zika viruses.

CAUSED BY

 infected female Aedes mosquitoes, particularly Aedes aegypti or Aedes albopictus

INFECTS

Primarily humans

SYMPTOMS

High fever, severe headaches, pain behind the eyes, joint and muscle pain, rash, and mild bleeding

VIRUS FAMILY

Flaviviridae family, genus Flavivirus

Arboviruses are a group of viruses that are primarily transmitted to humans and other vertebrates through the bites of arthropods, particularly mosquitoes and ticks. These viruses are responsible for a wide range of diseases in humans and animals. The most common arboviral diseases include dengue fever, Zika virus, West Nile virus, chikungunya, and various forms of encephalitis. IBT Bioservices is a world leader in producing and offering unique reagents for arbovirus research. we offers a diverse array of products and services designed to facilitate arbovirus research, ranging from viral proteins to antiserum and antibodies.

Our comprehensive range includes

Antiserum

Purified monoclonal and polyclonal antibodies

Recombinant proteins

Rest assured, our reagents are of exceptional quality, and they are available for purchase to support your research endeavors.

Our preclinical testing services for arboviruses encompass a wide range of assessments, including:

Antiviral Assays

Using advanced cellular and molecular techniques, we evaluate the antiviral activity of potential drugs against the Dengue virus. These in vitro studies help identify compounds that can effectively inhibit viral replication, reduce viral load, and mitigate the disease’s progression. We investigate the mechanism of action of potential treatments and their impact on viral replication and host cell interactions. Assays available include microneutralization, qPCR, plaque assays, PRNT, to name a few.

Pharmacokinetic and Toxicology Studies

Understanding how potential treatments are absorbed, distributed, metabolized, and eliminated by the body is crucial. Our comprehensive pharmacokinetic studies provide valuable insights into the drug’s behavior, bioavailability, and optimal dosage. Additionally, toxicology evaluations ensure the safety of the treatment candidates, assessing potential adverse effects and determining the appropriate dosage range.

Animal Models

To mimic Dengue virus infection and assess the safety and efficacy of potential treatments, IBT has established the Ag129 disease model. We can closely monitor key parameters, including viral load, disease progression, and survival rates, to evaluate the effectiveness of the tested therapies. Our in vivo studies provide valuable data on the treatment’s ability to control viral replication, reduce disease severity, and improve overall outcomes.Available Animal Species and Strains: AG129 Mice, BALB/c Mice.

 

IBT has a selection of Dengue viruses strains available for the assessment of a range of therapeutics and vaccines.

Dengue Virus-2 S221

Dengue Virus-2 D2Y98P

Dengue Virus Serotypes 1-4

AG129 mice were challenged with 200uL of 5.00E+05 PFU/mouse of Dengue virus 2- D2Y98P, followed by an antibody treatment 24-hour post-challenge. The mean time of death for this model is day 5.

At IBT Bioservices, we are committed to advancing the field of Dengue virus research and development through reliable and accurate preclinical testing services. Our dedication to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this global health challenge.Contact us today to learn more about how our in vitro and in vivo preclinical testing services can accelerate the development of promising treatments for the Dengue virus.